US 12,227,497 B2
Solid forms of(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
Antonio J. Barbosa, Ave Maria, FL (US)
Assigned to ATEGRIN, INC., Miami, FL (US)
Filed by Ategrin, Inc., Miami, FL (US)
Filed on Nov. 1, 2022, as Appl. No. 17/978,848.
Application 17/978,848 is a continuation of application No. 17/703,839, filed on Mar. 24, 2022, abandoned.
Application 17/703,839 is a continuation of application No. 17/387,850, filed on Jul. 28, 2021, abandoned.
Application 17/387,850 is a continuation of application No. 16/675,097, filed on Nov. 5, 2019, granted, now 11,111,239, issued on Sep. 7, 2021.
Application 16/675,097 is a continuation of application No. 15/735,560, granted, now 10,723,726, issued on Jul. 28, 2020, previously published as PCT/US2016/037067, filed on Jun. 10, 2016.
Claims priority of provisional application 62/275,655, filed on Jan. 6, 2016.
Claims priority of provisional application 62/175,066, filed on Jun. 12, 2015.
Prior Publication US 2023/0227443 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/06 (2006.01); A61P 35/00 (2006.01); C07C 215/08 (2006.01)
CPC C07D 417/06 (2013.01) [A61P 35/00 (2018.01); C07C 215/08 (2013.01); C07B 2200/13 (2013.01)] 10 Claims
 
1. A method for treating an autoimmune or inflammatory disease, the method comprising: administering to a patient having an autoimmune or inflammatory disease a choline salt or a meglumine salt of a compound according to Formula (I)

OG Complex Work Unit Chemistry
or a crystalline form thereof.